Overview of CD24 as a new molecular marker in ovarian cancer - PubMed (original) (raw)
Review
. 2019 Mar;234(3):2134-2142.
doi: 10.1002/jcp.27581. Epub 2018 Oct 14.
Affiliations
- PMID: 30317611
- DOI: 10.1002/jcp.27581
Review
Overview of CD24 as a new molecular marker in ovarian cancer
Vahideh Tarhriz et al. J Cell Physiol. 2019 Mar.
Abstract
Ovarian cancer (OC) is the fifth leading cause of cancer-related death among women. The high mortality rate is due to lack of early symptoms, late diagnosis, limited treatment options, and also emerging of drug resistance. Todays, molecular markers have become promising in tumor-targeted therapy. Several molecular markers have been known in OC immunotherapy. Identification of the specific molecular markers with prognostic significance is interested. CD24 is a small sialoglycoprotein which is localized in lipid rafts through its glycosylphosphatidylinositol (GPI) anchor. It has been reported that CD24 is overexpressed in many cancers including OC. Also, CD24 is identified as a cancer stem cell marker in OC. The CD24 expression is associated with the development, invasion, and metastasis of cancer cells. The exact role of CD24 in cancer cells is not clearly understood. Recently, CD24 has been identified as an independent prognostic marker of survival in patients with OC. In this study, we reviewed the molecular targets in OC immune-targeted therapy and also presented an overview of the new molecular marker CD24 and its association with the OC by reviewing the recent literature.
Keywords: CD24; ovarian cancer; tumor marker.
© 2018 Wiley Periodicals, Inc.
Similar articles
- CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
Nakamura K, Terai Y, Tanabe A, Ono YJ, Hayashi M, Maeda K, Fujiwara S, Ashihara K, Nakamura M, Tanaka Y, Tanaka T, Tsunetoh S, Sasaki H, Ohmichi M. Nakamura K, et al. Oncol Rep. 2017 Jun;37(6):3189-3200. doi: 10.3892/or.2017.5583. Epub 2017 Apr 19. Oncol Rep. 2017. PMID: 28440503 Free PMC article. - Expression of CD24 in plasma, exosome and ovarian tissue samples of serous ovarian cancer patients.
Soltész B, Lukács J, Szilágyi E, Márton É, Szilágyi Bónizs M, Penyige A, Póka R, Nagy B. Soltész B, et al. J Biotechnol. 2019 Jun 10;298:16-20. doi: 10.1016/j.jbiotec.2019.03.018. Epub 2019 Apr 5. J Biotechnol. 2019. PMID: 30959137 - RCD24, B7-H4 and PCNA expression and clinical significance in ovarian cancer.
Zheng C, Yang R. Zheng C, et al. J BUON. 2019 Mar-Apr;24(2):715-719. J BUON. 2019. PMID: 31128028 - Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity.
Jaggupilli A, Elkord E. Jaggupilli A, et al. Clin Dev Immunol. 2012;2012:708036. doi: 10.1155/2012/708036. Epub 2012 May 30. Clin Dev Immunol. 2012. PMID: 22693526 Free PMC article. Review. - Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Mahdian-Shakib A, Dorostkar R, Tat M, Hashemzadeh MS, Saidi N. Mahdian-Shakib A, et al. Biomed Pharmacother. 2016 Dec;84:592-600. doi: 10.1016/j.biopha.2016.09.087. Epub 2016 Sep 30. Biomed Pharmacother. 2016. PMID: 27694003 Review.
Cited by
- Chemotherapy drug potency assessment method of ovarian cancer cells by digital holography microscopy.
Liu Y, Xiao W, Zhang H, Xin L, Li X, Pan F. Liu Y, et al. Biomed Opt Express. 2022 Jul 27;13(8):4370-4385. doi: 10.1364/BOE.465149. eCollection 2022 Aug 1. Biomed Opt Express. 2022. PMID: 36032571 Free PMC article. - The complex role of macrophages in pancreatic cancer tumor microenvironment: a review on cancer progression and potential therapeutic targets.
Lorestani P, Dashti M, Nejati N, Habibi MA, Askari M, Robat-Jazi B, Ahmadpour S, Tavakolpour S. Lorestani P, et al. Discov Oncol. 2024 Aug 26;15(1):369. doi: 10.1007/s12672-024-01256-x. Discov Oncol. 2024. PMID: 39186144 Free PMC article. Review. - Macrophages in Glioblastoma Development and Therapy: A Double-Edged Sword.
Wu M, Shi Y, Zhu L, Chen L, Zhao X, Xu C. Wu M, et al. Life (Basel). 2022 Aug 12;12(8):1225. doi: 10.3390/life12081225. Life (Basel). 2022. PMID: 36013403 Free PMC article. Review. - Involvement of the Estrogen and Progesterone Axis in Cancer Stemness: Elucidating Molecular Mechanisms and Clinical Significance.
Chen B, Ye P, Chen Y, Liu T, Cha JH, Yan X, Yang WH. Chen B, et al. Front Oncol. 2020 Sep 4;10:1657. doi: 10.3389/fonc.2020.01657. eCollection 2020. Front Oncol. 2020. PMID: 33014829 Free PMC article. Review. - New approaches in ovarian cancer based on genetics and carcinogenesis hypotheses (Review).
Mogos RA, Popovici R, Tanase AE, Calistru T, Popovici P, Grigore M, Carauleanu A. Mogos RA, et al. Exp Ther Med. 2022 Jun;23(6):423. doi: 10.3892/etm.2022.11351. Epub 2022 May 4. Exp Ther Med. 2022. PMID: 35607380 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical